Everyone argues about BPC-157; almost nobody publishes data about it. The clinical literature is mostly rodent studies, the FDA's own reviewers call the human evidence thin, and yet the compound headlined a July 2026 advisory-committee vote 1 precisely because so many people use it. The piece missing from every article is the middle: what do the people using it actually do?
We can answer a version of that. ZyraTrack's research pipeline continuously indexes public community discussion (forums, comment threads, video transcripts) alongside the scientific literature. From 2,805 public mentions of BPC-157, our extraction pipeline identified 244 structured human usage reports from 182 distinct people — reports concrete enough to carry a dose, a route, or a schedule. This is what they say.
Read this first. These are self-reports from anonymous people on the internet, extracted by an automated pipeline under human-audited rules. They describe behavior — not efficacy, not safety. Nothing here is a recommendation or medical advice. It is a census, and censuses have biases we name at the end.
The convergence: everyone says 500
The most striking thing in the data is agreement. Across both routes, the median reported dose is 500 mcg, and 500 mcg is also the single most-reported value:
| Reported dose | Injection reports | Oral reports |
|---|---|---|
| 250 mcg | 23 | 3 |
| 500 mcg | 33 | 35 |
| 501–1,000 mcg | 13 | 3 |
| 1,001–5,000 mcg | 5 | 2 |
| Milligram-scale (250–1,000 mg) | 2 | 7 |
This contradicts a piece of common folklore. The usual claim is that oral BPC-157 requires far higher amounts than injection to survive digestion — yet the people actually taking it orally report the same 500 mcg as the injectors. Whether that reflects informed choice, or simply everyone copying the same number from the same forum posts, the data cannot say. What it does say is that the "oral needs more" belief is not what shows up in practice.
The collision hiding inside the agreement
Now the part that matters for anyone's safety. Look again at that last row.
Seven oral reports describe doses of 250 to 1,000 milligrams — a thousandfold above the median. They are not extraction errors; we read every one of them by hand. They are people using commercial oral capsule products, which are manufactured and labelled in milligrams:
"I take two capsules a day each 500 mg." "I've started taking oral bpc157 which are 500mg capsules and on [the] bottle it suggests 1 twice a day."
So two vocabularies coexist in one community. The injectable world talks in micrograms; the capsule world reads milligrams off a label. Both say "500." They differ by a factor of a thousand.
And the collision is not hypothetical. Two reports in the dataset describe injecting milligram-scale doses:
"I started 5 days ago with 500mg of each injected once a day."
Whether that is a typo, a misreading of a label, or a genuine event, it is the exact error mode this community should be loudest about — and, as far as we can find, nobody has quantified it before. If you take one thing from this page: the unit is not a detail. Write it down every time.
Schedule: daily, and short
Of reports that state a frequency, daily dominates on both routes — 41 injection reports and 25 oral at once per day, with a smaller twice-daily group (8 and 4). Weekly or intermittent schedules barely appear. The typical stated run is two to four weeks, consistent with the injury-recovery framing that dominates the discussions, and a sizable tail — about a third of reports that state a duration — stretches to one to three months. Runs beyond that are rare, and one report describes two years of continuous daily use.
The company it keeps
Because reports link per person, we can see what else the same people use:
| Also reported by the same person | People (of 182) |
|---|---|
| TB-500 | 42 |
| Retatrutide | 11 |
| GHK-Cu | 7 |
| MOTS-c | 7 |
| Tesamorelin | 4 |
TB-500 alongside BPC-157 is the community's canonical repair stack, and at roughly a quarter of all people in the dataset, it is not folklore — it is the norm. Practically, that means the FDA's compounding decision addresses a compound that is rarely used alone.
The second row is newer. A visible group of retatrutide users — a GLP-1 weight-loss compound — also report BPC-157. Two communities that used to be separate are now overlapping in the same bodies.
What people say happened, and why to distrust it
Of the 244 reports, 65 carry an explicitly positive outcome, 5 an explicitly negative one, and 7 mention an adverse effect. The adverse reports are specific — persistent diarrhea, heart palpitations, "debilitating headaches" that ended a protocol — and the negative-outcome reports are mostly "no result":
"used BPC-157 (250mcg twice a day) and TB-500 for over 3 months, didn't see any results."
Resist the obvious reading of that 65-to-5 ratio. An uncontrolled, self-selected, publicly-posted sample produces glowing numbers for essentially any intervention: people who felt nothing rarely write a post, and people who had a bad time often stop reading the forum entirely. The honest interpretation is that this dataset cannot measure whether BPC-157 works or how safe it is — it can only measure what gets said. We publish the ratio for transparency, not as a finding.
The evidence gap, stated plainly
Set 244 human usage reports against the published science and the asymmetry is stark. Our research index — 681 primary papers — surfaces plentiful rodent wound-healing and gut-protection work for BPC-157, and almost nothing at human-trial grade. That is precisely the gap FDA scientists described in July 2026 when they cited short, underpowered studies — before the advisory committee voted 8-6 to recommend the compound for compounding anyway 1. The final decision now moves through formal rulemaking, expected to take 12 to 24 months 2.
So the situation this page documents — wide real-world use, thin formal evidence, regulation in motion — will persist for a while. The useful response is neither to pretend the use isn't happening nor to dress it up as evidence. It is to measure carefully, label units, and keep those two things apart.
Methodology and limitations
Community reports come from ZyraTrack's continuously-updated index of public peptide discussion (81,398 indexed passages at this snapshot). An extraction pipeline identifies concrete usage claims — dose, unit, route, schedule, subject — which pass through tiering rules and human spot-checks; animal reports, study descriptions, and hearsay are tagged and excluded from the human counts here. Ambiguous units are flagged rather than silently "corrected," which is why the milligram cluster above survives in the data instead of being normalised away.
Known limitations, plainly: the sample is self-selected and skews toward people who post; one person can appear in several reports (we de-duplicate by person where a stable identity exists, which is how the 182 figure is derived); route is unstated in 77 reports and those are excluded from the route comparisons; and nothing here is verified against a purchase, a lab test, or a scale. Counts are a point-in-time snapshot (14 August 2026) and will move as the corpus grows.
Our full corpus methodology is on the methodology page, and the research library is browsable at /research/. If you want a cut of this data we haven't published — by route, by stack, over time — write to us and we will run it.
ZyraTrack is a research and education tool. We never sell or source compounds, never recommend doses, and refuse sourcing questions. If you use anything discussed here, that is between you and a clinician; our job is only to make the numbers around it honest.